MeiraGTx Holdings Plc Stock News

LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, P

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 55.10% and 202.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) saw an uptick in trading volume on Tuesday . 5,580 shares traded hands during mid-day trading, a decline of 97% from the previous sessions volume of 187,077 shares.The stock last traded at $22.23 and had previously closed at $21.23. Several research firms have issued reports on MGTX. Bank of []

MeiraGTx says it has a triggering drug that can be used to turn implanted genes on and off in people. The technology could lessen the cost of treatment for many illnesses.

LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX ), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and conference call on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ET highlighting the Company''s gene regulation platforms. MeiraGTx''s R&D Day webcast will feature a presentation by Alexandria Forbes, Ph.D., President and Chief Executive Officer. The event will provide a detailed overview of the Company''s gene regulation platforms including promoter engineering and MeiraGTx''s proprietary platform driven by novel synthetic riboswitches controlled by oral small molecules. The presentation will be followed by an audience question and answer session. MeiraGTx''s virtual R&D Day details are as follows: Wednesday, December 15, 2021, from Full story available on Benzinga.com

LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 7, 2021, at 8:00 a.m. ET.

Vanguard Group Inc. lessened its stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 5.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 182,470 shares of the companys stock after selling 11,195 shares during the quarter. Vanguard Group Inc.s holdings in MeiraGTx were worth $2,829,000 at the end of the most recent quarter. []

Infinity Pharmaceuticals, Inc. (INFI) with the stream of 1.80% also noticed, India MeiraGTx Holdings plc (MGTX) encountered a rapid change of 3.16% in the last hour of Wednesdays trading session. The post Active Stock to Observe: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), MeiraGTx Holdings plc (NASDAQ:MGTX) appeared first on Stocks Equity .

Related Stocks: MGTX ,

Zacks Investment Research downgraded shares of MeiraGTx (NASDAQ:MGTX) from a hold rating to a sell rating in a report issued on Saturday, Zacks.com reports. According to Zacks, MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments []

Zacks Investment Research downgraded shares of MeiraGTx (NASDAQ:MGTX) from a hold rating to a sell rating in a research report released on Saturday morning, Zacks.com reports. According to Zacks, MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene []

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st